[1] |
WANG Xinli, XU Xiaqing, FANG Hanbing, GUO Yuzhong.
Study of TPA on enhancing the anti-tumor effects of cisplatin and reducing its renal toxicity
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 535-543.
|
[2] |
CUI Hua, YAN Hongxia, YIN Mei.
Effects of down-regulating lncRNA LINC00176 on cisplatin resistance and autophagy in lung cancer A549/DDP cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 616-623.
|
[3] |
LIU Yunfan, DU Yuemei, LIU Xiaoyi, GAO Liping.
Effects of lycium barbarum polysaccharides on cis-dichlorodiamineplatinum (II)-induced apoptosis in mouse testis sertoli cells TM4#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 624-630.
|
[4] |
CHENG Jianping, LI Zhen, ZHAO Xiaolin, YANG Mengyuan, JI Xiwei, YU Jiufei.
Research on the expression of miR-186-5p in serum of patients with colon cancer#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1097-1104.
|
[5] |
TENG Xiaojing, DONG Xueyan, WANG Zhiyi, YU Daojun, WANG Xianjun.
Experimental study of Fuzheng Kangfu mixture combined with cisplatin on apoptosis of the gastric cancer cell SGC7901
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 744-749.
|
[6] |
ZHENG Zhongqiu, XIE Bojian, CUI Binbin, KE Yichen, LIN Yi.
miR-106 b expression in breast cancer tissues and mechanism of enhancing cisplatin sensitivity in breast cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 541-545.
|
[7] |
LI Lin, WANG Wenhong, WANG Hongmei.
PDCD4 enhances the sensitivity mechanism of nasopharyngeal carcinoma cell line CNE1 to cisplatin chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 9-13.
|
[8] |
QIN Boyu, WANG Gang, QI Xiaoguang, WANG Yajie, SUN Qiong, SUN Shengjie.
Inhibitory effect of cisplatin combined with zoledronic acid on the cell proliferation of lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1027-1030.
|
[9] |
LIU Wencheng,TAN Buzhen,ZHAN Xinlu,HU Hui,HUANG Genhua,CAO Qing.
Study on the cisplatin-sensitization effect of tripterygium glycosides on cisplatin-resistant human epithelial ovarian cancer cells (SKOV3/DDP) in vitro
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1364-1370.
|
[10] |
ZHANG Hong, GU Kang-sheng.
Clinical observation of ERCC1 protein expression and cisplatin based chemotherapy on advanced esophageal cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 546-551.
|
[11] |
WU Chun-yan, WANG Wei, CHEN Xin, CHEN Dong-yun, RUI Jing.
Efficacy and therapeutic mechanism of recombinant human endostatin on malignant ascites in mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(5): 507-511.
|
[12] |
JIN Yi-feng, HE Bei, LIU Dong-hua, WAN Ying.
Relationship between ERCC1,Bcl-2 expression and cisplatin intervention in human lung adenocarcinoma cell lines
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 764-768.
|
[13] |
ZHAO Wen-ying, CHEN Dong-yun, CHEN Jing-hua.
Observation of short-term therapeutic and adverse effect of lentinan and gemcitabine plus cisplatin as the first-line treatment for advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 71-77.
|
[14] |
HAO Ji-qing, MA Qiang, LIU Peng-kun.
Comparison of GL (Gemicitabine plus Lobaplatin) and GP(Gemicitabine plus Cisplatin) in the treatment of metastatic breast cancer patients with anthracycline and taxane resistance
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 554-558.
|
[15] |
WANG Gui-ping, LIAO Hong-ying, WEI Min, WANG Yan, ZHOU Qiong, LIN Zhu-zhen, ZHANG Yan-tao.
Synergy inhibition effect of 17-AAG in combination with cisplatin on lung adenocarcinoma A549 cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(11): 1240-1244.
|